ACI-19626 (TDP-43 PET Tracer)
TDP-43 Proteinopathies
PreclinicalActive
Key Facts
About AC Immune
Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.
View full company profileTherapeutic Areas
Other TDP-43 Proteinopathies Drugs
| Drug | Company | Phase |
|---|---|---|
| Anti-TDP-43 Antibody | AC Immune | Preclinical |